WO2017136792A8 - Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier - Google Patents

Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier Download PDF

Info

Publication number
WO2017136792A8
WO2017136792A8 PCT/US2017/016603 US2017016603W WO2017136792A8 WO 2017136792 A8 WO2017136792 A8 WO 2017136792A8 US 2017016603 W US2017016603 W US 2017016603W WO 2017136792 A8 WO2017136792 A8 WO 2017136792A8
Authority
WO
WIPO (PCT)
Prior art keywords
gut
benefit
mucosal barrier
tightened
treat diseases
Prior art date
Application number
PCT/US2017/016603
Other languages
French (fr)
Other versions
WO2017136792A2 (en
WO2017136792A3 (en
Inventor
Paul F. Miller
Vincent M. ISABELLA
Jonathan W. KOTULA
Dean Falb
Adam B. FISHER
Yves Millet
Ning Li
Original Assignee
Synlogic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/020530 external-priority patent/WO2016141108A1/en
Priority claimed from PCT/US2016/032565 external-priority patent/WO2016183532A1/en
Priority claimed from PCT/US2016/039444 external-priority patent/WO2016210384A2/en
Priority claimed from PCT/US2016/050836 external-priority patent/WO2017074566A1/en
Priority claimed from US15/260,319 external-priority patent/US11384359B2/en
Priority claimed from PCT/US2016/069052 external-priority patent/WO2017123418A1/en
Priority to CA3013770A priority Critical patent/CA3013770A1/en
Application filed by Synlogic, Inc. filed Critical Synlogic, Inc.
Priority to US16/074,559 priority patent/US20210161976A1/en
Priority to EP17705544.9A priority patent/EP3411051A2/en
Priority to AU2017213646A priority patent/AU2017213646A1/en
Priority to PCT/US2017/017552 priority patent/WO2017139697A1/en
Priority to PCT/US2017/017563 priority patent/WO2017139708A1/en
Publication of WO2017136792A2 publication Critical patent/WO2017136792A2/en
Publication of WO2017136792A3 publication Critical patent/WO2017136792A3/en
Publication of WO2017136792A8 publication Critical patent/WO2017136792A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/52—Propionic acid; Butyric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
PCT/US2017/016603 2016-02-04 2017-02-03 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier WO2017136792A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2017213646A AU2017213646A1 (en) 2016-02-04 2017-02-03 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
EP17705544.9A EP3411051A2 (en) 2016-02-04 2017-02-03 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US16/074,559 US20210161976A1 (en) 2016-02-04 2017-02-03 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
CA3013770A CA3013770A1 (en) 2016-02-04 2017-02-03 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
PCT/US2017/017563 WO2017139708A1 (en) 2016-02-10 2017-02-10 Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
PCT/US2017/017552 WO2017139697A1 (en) 2016-02-10 2017-02-10 Bacteria engineered to treat diseases associated with hyperammonemia

Applications Claiming Priority (34)

Application Number Priority Date Filing Date Title
US201662291461P 2016-02-04 2016-02-04
US201662291468P 2016-02-04 2016-02-04
US201662291470P 2016-02-04 2016-02-04
US62/291,470 2016-02-04
US62/291,468 2016-02-04
US62/291,461 2016-02-04
USPCT/US2016/020530 2016-03-02
PCT/US2016/020530 WO2016141108A1 (en) 2015-03-02 2016-03-02 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
PCT/US2016/032565 WO2016183532A1 (en) 2015-05-13 2016-05-13 Bacteria engineered to treat a disease or disorder
USPCT/US2016/032565 2016-05-13
US201662347508P 2016-06-08 2016-06-08
US201662347576P 2016-06-08 2016-06-08
US62/347,576 2016-06-08
US62/347,508 2016-06-08
US201662348620P 2016-06-10 2016-06-10
US62/348,620 2016-06-10
US201662354682P 2016-06-24 2016-06-24
PCT/US2016/039444 WO2016210384A2 (en) 2015-06-25 2016-06-24 Bacteria engineered to treat metabolic diseases
USPCT/US2016/039444 2016-06-24
US62/354,682 2016-06-24
US201662362954P 2016-07-15 2016-07-15
US62/362,954 2016-07-15
US201662385235P 2016-09-08 2016-09-08
US15/260,319 2016-09-08
US15/260,319 US11384359B2 (en) 2014-12-22 2016-09-08 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
USPCT/US2016/050836 2016-09-08
US62/385,235 2016-09-08
PCT/US2016/050836 WO2017074566A1 (en) 2015-10-30 2016-09-08 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US201662423170P 2016-11-16 2016-11-16
US62/423,170 2016-11-16
US201662439871P 2016-12-28 2016-12-28
USPCT/US2016/069052 2016-12-28
US62/439,871 2016-12-28
PCT/US2016/069052 WO2017123418A1 (en) 2016-01-11 2016-12-28 Bacteria engineered to treat metabolic diseases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/260,319 Continuation-In-Part US11384359B2 (en) 2014-12-22 2016-09-08 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier

Publications (3)

Publication Number Publication Date
WO2017136792A2 WO2017136792A2 (en) 2017-08-10
WO2017136792A3 WO2017136792A3 (en) 2017-09-08
WO2017136792A8 true WO2017136792A8 (en) 2017-09-28

Family

ID=59500293

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/016603 WO2017136792A2 (en) 2016-02-04 2017-02-03 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier

Country Status (4)

Country Link
EP (1) EP3411051A2 (en)
AU (1) AU2017213646A1 (en)
CA (1) CA3013770A1 (en)
WO (1) WO2017136792A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291693B2 (en) 2015-06-25 2022-04-05 Synlogic Operating Company, Inc. Bacteria engineered to treat metabolic diseases
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
WO2017019895A1 (en) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Evolution of talens
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
WO2020223345A1 (en) 2019-04-29 2020-11-05 Antipov Eugene Enumeration of genetically engineered microorganisms by live cell counting techniques
US20230172997A1 (en) * 2020-05-26 2023-06-08 Synlogic Operating Company, Inc. Recombinant bacteria for production of indole-3-acetic acid (iaa) and uses thereof
US20230364162A1 (en) * 2020-09-28 2023-11-16 The Regents Of The University Of Michigan Methods and compositions for intestinal inflammation
CN112458033B (en) * 2020-11-16 2023-01-24 四川农业大学 Attenuated salmonella typhimurium and construction method and application thereof
CA3200887A1 (en) 2020-12-02 2022-06-09 Michael James Engineered microorganisms
WO2023010050A1 (en) * 2021-07-28 2023-02-02 The Broad Institute, Inc. Methods of periplasmic phage-assisted continuous evolution
EP4162946A1 (en) * 2021-10-05 2023-04-12 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Kynurenine aminotransferase and products thereof for the treatment of inflammatory bowel diseases
CN114369146B (en) * 2022-01-14 2023-05-23 上海交通大学医学院附属仁济医院 Acremonium Amuc-2172 protein and preparation method and application thereof
EP4295859A1 (en) * 2022-06-20 2023-12-27 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Kynurenine aminotransferase and products thereof for the treatment of arthritic diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
WO2008143704A2 (en) * 2006-12-01 2008-11-27 Gevo, Inc. Engineered microorganisms for producing n-butanol and related methods
WO2012088461A2 (en) 2010-12-23 2012-06-28 Biogen Idec Inc. Linker peptides and polypeptides comprising same
US20160206666A1 (en) * 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
CN107636146A (en) * 2015-03-02 2018-01-26 同生公司 It is engineered to treat the bacterium of the disease for the gastrointestinal mucosal barrier benefited from the alimentary canal inflammation of reduction and/or tightened up

Also Published As

Publication number Publication date
EP3411051A2 (en) 2018-12-12
WO2017136792A2 (en) 2017-08-10
CA3013770A1 (en) 2017-08-10
WO2017136792A3 (en) 2017-09-08
AU2017213646A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
WO2016141108A8 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
WO2017136792A8 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
EP4234551A3 (en) Pyridazinones as parp7 inhibitors
SG10201907660YA (en) Use of short chain fatty acids in cancer prevention
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
MX2018003331A (en) Administration of deuterated cftr potentiators.
MX2021010868A (en) Bacterium of the christensenellaceae family for the prevention and/or treatment of chronic inflammatory diseases and/or inflammatory gastrointestinal diseases and/or cancers.
WO2017011820A3 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017027810A3 (en) Compositions and methods that promote the hypoxia response for treatment of mitochondrial dysfunction and oxidative stress disorders
WO2017136795A8 (en) Bacteria engineered to treat diseases associated with tryptophan metabolism
WO2014151456A3 (en) Treatment of inflammatory diseases
WO2017139697A8 (en) Bacteria engineered to treat diseases associated with hyperammonemia
WO2016200614A3 (en) Bacteria engineered to treat diseases associated with hyperammonemia
EP4218736A3 (en) Compositions comprising 15-hepe
WO2018226992A8 (en) Tau aggregation inhibitors
EP3639833A4 (en) Agent for the prevention or treatment of fat-related diseases and/or inflammation
WO2017035176A8 (en) Method of preventing or treating obesity with an emc10 inhibitor
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
EP3413904A4 (en) Herbal compositions and methods for the prevention and treatment of plant or nail infections
WO2017075540A9 (en) Methods and compositions for the treatment of amyloidosis
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
AU2016298962A8 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
WO2017009257A3 (en) Pectin compositions for preventing and treating inflammatory diseases
WO2016109002A3 (en) Methods and compositions for the treatment of radiation-related disorders
MX2020001256A (en) Compounds for the prevention and treatment of medical disorders and uses thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17705544

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 3013770

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017213646

Country of ref document: AU

Date of ref document: 20170203

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017705544

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017705544

Country of ref document: EP

Effective date: 20180904